What does CYTOMICS CONSULTING do?

CYTOMICS CONSULTING is a specialist medical practice in Gent. Private Limited, started on 27 January 2020, 1 establishment.

What is the address of CYTOMICS CONSULTING?

The registered office of CYTOMICS CONSULTING is located at Handekenskruidstraat 11, 9041 Gent.

Is CYTOMICS CONSULTING still active?

Yes. According to the CBE (31 October 2026) CYTOMICS CONSULTING is active, legal situation “Normale toestand”, started on 27 January 2020.

Is CYTOMICS CONSULTING registered on Peppol?

Yes, CYTOMICS CONSULTING is registered on the Peppol network with ID 0208:0742547668.

What is the enterprise number of CYTOMICS CONSULTING?

The enterprise number of CYTOMICS CONSULTING is BE0742547668.

When was CYTOMICS CONSULTING founded?

CYTOMICS CONSULTING was founded on 27 January 2020.

Who are the directors of CYTOMICS CONSULTING?

According to the 2025 annual accounts, the directors of CYTOMICS CONSULTING are: Geert MARTENS, Mieke Keppens.

Is CYTOMICS CONSULTING a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 January 2020; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did CYTOMICS CONSULTING make in 2025?

CYTOMICS CONSULTING posted a profit after taxes of € 371,101 in financial year 2025.

What is the revenue of CYTOMICS CONSULTING?

As a small company, CYTOMICS CONSULTING is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 622,830.

CYTOMICS CONSULTING (Private Limited) - Gent

Dossier CYTOMICS CONSULTING, printed on 31 October 2026 from databakkes.be/en/0742547668/cytomics-consulting. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

CYTOMICS CONSULTING from Gent, company number BE0742547668, closed financial year 2025 with a result of € 371,101 after tax. For that financial year CYTOMICS CONSULTING recorded a gross margin of € 622,830 and equity of € 1.7 million. Compared with financial year 2024, the result moved from € 357,506 to € 371,101. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 14, 2026.

What it is worth Growing

€ 1.7 million

▲ 11% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 371,101

▲ 4% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 100,965

▼ 52% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 200,000 paid out

54 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Wage cost

€ 34,642

▲ € 33,642 vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 77,906

▼ 14% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 6 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 157,261

▼ 14% vs 2024

€ 24,817 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.

Owed to suppliers

€ 3,149

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 67,662

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 552,851 Gross margin 2022: € 552,851 First fiscal year in the series	€ 470,743 Gross margin 2023: € 470,743 ▼ 15% vs 2022 (€ 552,851) Unfavourable step	€ 517,470 Gross margin 2024: € 517,470 ▲ 10% vs 2023 (€ 470,743) Favourable step	€ 622,830 Gross margin 2025: € 622,830 ▲ 20% vs 2024 (€ 517,470) Favourable step	▲ 20%
Profit after taxes	€ 313,598 Profit after taxes 2022: € 313,598 First fiscal year in the series	€ 286,607 Profit after taxes 2023: € 286,607 ▼ 9% vs 2022 (€ 313,598) Unfavourable step	€ 357,506 Profit after taxes 2024: € 357,506 ▲ 25% vs 2023 (€ 286,607) Favourable step	€ 371,101 Profit after taxes 2025: € 371,101 ▲ 4% vs 2024 (€ 357,506) Favourable step	▲ 4%
Equity	€ 1,247,761 Equity 2022: € 1,247,761 First fiscal year in the series	€ 1,374,061 Equity 2023: € 1,374,061 ▲ 10% vs 2022 (€ 1,247,761) Favourable step	€ 1,500,361 Equity 2024: € 1,500,361 ▲ 9% vs 2023 (€ 1,374,061) Favourable step	€ 1,671,461 Equity 2025: € 1,671,461 ▲ 11% vs 2024 (€ 1,500,361) Favourable step	▲ 11%
Total debts	€ 645,032 Total debts 2022: € 645,032 First fiscal year in the series	€ 514,439 Total debts 2023: € 514,439 ▼ 20% vs 2022 (€ 645,032) Favourable step	€ 413,047 Total debts 2024: € 413,047 ▼ 20% vs 2023 (€ 514,439) Favourable step	€ 427,629 Total debts 2025: € 427,629 ▲ 4% vs 2024 (€ 413,047) Unfavourable step	▲ 4%
Cash	€ 485,133 Cash 2022: € 485,133 First fiscal year in the series	€ 77,399 Cash 2023: € 77,399 ▼ 84% vs 2022 (€ 485,133) Unfavourable step	€ 212,141 Cash 2024: € 212,141 ▲ 174% vs 2023 (€ 77,399) Favourable step	€ 100,965 Cash 2025: € 100,965 ▼ 52% vs 2024 (€ 212,141) Unfavourable step	▼ 52%
Land & buildings	€ 489,432 Land & buildings 2022: € 489,432 First fiscal year in the series	€ 476,574 Land & buildings 2023: € 476,574 ▼ 3% vs 2022 (€ 489,432) Unchanged	€ 463,716 Land & buildings 2024: € 463,716 ▼ 3% vs 2023 (€ 476,574) Unchanged	€ 450,858 Land & buildings 2025: € 450,858 ▼ 3% vs 2024 (€ 463,716) Unchanged	▼ 3%
Retained profit	€ 1,227,761 Retained profit 2022: € 1,227,761 First fiscal year in the series	€ 1,354,061 Retained profit 2023: € 1,354,061 ▲ 10% vs 2022 (€ 1,227,761) Favourable step	€ 1,480,361 Retained profit 2024: € 1,480,361 ▲ 9% vs 2023 (€ 1,354,061) Favourable step	€ 1,651,461 Retained profit 2025: € 1,651,461 ▲ 12% vs 2024 (€ 1,480,361) Favourable step	▲ 12%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 160,307 Dividend 2023: € 160,307 Unchanged (€ 0) Unchanged	€ 231,206 Dividend 2024: € 231,206 ▲ 44% vs 2023 (€ 160,307) Unchanged	€ 200,000 Dividend 2025: € 200,000 ▼ 13% vs 2024 (€ 231,206) Unchanged	▼ 13%
Bank debt	€ 234,090 Bank debt 2022: € 234,090 First fiscal year in the series	€ 206,510 Bank debt 2023: € 206,510 ▼ 12% vs 2022 (€ 234,090) Favourable step	€ 181,901 Bank debt 2024: € 181,901 ▼ 12% vs 2023 (€ 206,510) Favourable step	€ 157,261 Bank debt 2025: € 157,261 ▼ 14% vs 2024 (€ 181,901) Favourable step	▼ 14%
Balance sheet total	€ 1,892,792 Balance sheet total 2022: € 1,892,792 First fiscal year in the series	€ 1,888,499 Balance sheet total 2023: € 1,888,499 Unchanged (€ 1,892,792) Unchanged	€ 1,913,407 Balance sheet total 2024: € 1,913,407 ▲ 1% vs 2023 (€ 1,888,499) Unchanged	€ 2,099,090 Balance sheet total 2025: € 2,099,090 ▲ 10% vs 2024 (€ 1,913,407) Unchanged	▲ 10%

Key figures of CYTOMICS CONSULTING, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CYTOMICS CONSULTING?

What happened at CYTOMICS CONSULTING in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 14, 2026 New annual accounts for financial year 2025: profit of € 371,101 (▲ 4% vs 2024). filed late Source: NBB ↗
Jan 27, 2020 New establishment in Gent. KBO
2020 Geert MARTENS became a director. NBB
2020 Mieke Keppens became a director. NBB
Jan 27, 2020 Start of the company according to the CBE. KBO

In short

From € 313,598 profit in 2022 to € 371,101 profit in 2025.

Paid € 517,078 in corporate taxes since 2022.

Best year ever: 2025, with € 371,101 profit.

Paid out € 591,512 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Geert MARTENS Mieke Keppens

NXTLAB

CYTOMICS CONSULTING

Behind CYTOMICS CONSULTING are Geert MARTENS and Mieke Keppens. Geert MARTENS is also behind NXTLAB.

Directors

According to the 2025 annual accounts

Geert MARTENS

Director

Also active at: NXTLAB

since 2020

Mieke Keppens

Director

since 2020

Establishments

Establishment units

Physical locations of this company

Registered office

Handekenskruidstraat 11

9041 Gent

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0742.547.668

VAT number

BE 0742.547.668

Registered office

Handekenskruidstraat 11, 9041 Gent

Names & denominations

CYTOMICS CONSULTING

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

27 January 2020

Peppol

Active · Active since 25 Mar 2026

Activities · NACE

Activiteiten van medisch specialisten

Overige vormen van onderwijs

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

View on CBE Public ↗ Annual accounts (NBB) ↗

CYTOMICS CONSULTING

Financials

What happened to CYTOMICS CONSULTING?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions